Brain endothelial CXCL12 attracts protective natural killer cells during ischemic stroke.
Beam-walk sensorimotor test
Blood–brain barrier
CNS
CXCR4
Cdh5
Flow cytometry
ILC1
NK cells
Photothrombotic stroke
Whole mount imaging
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
11 Jan 2023
11 Jan 2023
Historique:
received:
07
10
2022
accepted:
02
01
2023
entrez:
11
1
2023
pubmed:
12
1
2023
medline:
14
1
2023
Statut:
epublish
Résumé
The innate lymphoid cell (ILC) family consists of NK cells, ILC type 1, 2, 3 and lymphoid tissue inducer cells. They have been shown to play important roles in homeostasis and immune responses and are generally considered tissue resident. Not much is known about the presence of ILC members within the central nervous system and whether they are tissue resident in this organ too. Therefore, we studied the presence of all ILC members within the central nervous system and after ischemic brain insult. We used the photothrombotic ischemic lesion method to induce ischemic lesions within the mouse brain. Using whole-mount immunofluorescence imaging, we established that the ILCs were present at the rim of the lesion. We quantified the increase of all ILC members at different time-points after the ischemic lesion induction by flow cytometry. Their migration route via chemokine CXCL12 was studied by using different genetic mouse models, in which we induced deletion of Cxcl12 within the blood-brain barrier endothelium, or its receptor, Cxcr4, in the ILCs. The functional role of the ILCs was subsequently established using the beam-walk sensorimotor test. Here, we report that ILCs are not resident within the mouse brain parenchyma during steady-state conditions, but are attracted towards the ischemic stroke. Specifically, we identify NK cells, ILC1s, ILC2s and ILC3s within the lesion, the highest influx being observed for NK cells and ILC1s. We further show that CXCL12 expressed at the blood-brain barrier is essential for NK cells and NKp46 This study establishes the lack of ILCs in the mouse central nervous system at steady-state and their migration towards an ischemic brain lesion. Our data show a role for blood-brain barrier-derived CXCL12 in attracting protective NK cells to ischemic brain lesions and identifies a new CXCL12/CXCR4-mediated component of the innate immune response to stroke.
Sections du résumé
BACKGROUND
BACKGROUND
The innate lymphoid cell (ILC) family consists of NK cells, ILC type 1, 2, 3 and lymphoid tissue inducer cells. They have been shown to play important roles in homeostasis and immune responses and are generally considered tissue resident. Not much is known about the presence of ILC members within the central nervous system and whether they are tissue resident in this organ too. Therefore, we studied the presence of all ILC members within the central nervous system and after ischemic brain insult.
METHODS
METHODS
We used the photothrombotic ischemic lesion method to induce ischemic lesions within the mouse brain. Using whole-mount immunofluorescence imaging, we established that the ILCs were present at the rim of the lesion. We quantified the increase of all ILC members at different time-points after the ischemic lesion induction by flow cytometry. Their migration route via chemokine CXCL12 was studied by using different genetic mouse models, in which we induced deletion of Cxcl12 within the blood-brain barrier endothelium, or its receptor, Cxcr4, in the ILCs. The functional role of the ILCs was subsequently established using the beam-walk sensorimotor test.
RESULTS
RESULTS
Here, we report that ILCs are not resident within the mouse brain parenchyma during steady-state conditions, but are attracted towards the ischemic stroke. Specifically, we identify NK cells, ILC1s, ILC2s and ILC3s within the lesion, the highest influx being observed for NK cells and ILC1s. We further show that CXCL12 expressed at the blood-brain barrier is essential for NK cells and NKp46
CONCLUSIONS
CONCLUSIONS
This study establishes the lack of ILCs in the mouse central nervous system at steady-state and their migration towards an ischemic brain lesion. Our data show a role for blood-brain barrier-derived CXCL12 in attracting protective NK cells to ischemic brain lesions and identifies a new CXCL12/CXCR4-mediated component of the innate immune response to stroke.
Identifiants
pubmed: 36631780
doi: 10.1186/s12974-023-02689-x
pii: 10.1186/s12974-023-02689-x
pmc: PMC9835334
doi:
Substances chimiques
Chemokine CXCL12
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-16-ACHN-0011
Organisme : A*Midex
ID : chaire d'excellence
Organisme : Fondation pour la Recherche Médicale
ID : AJE20150633331
Informations de copyright
© 2023. The Author(s).
Références
PLoS One. 2012;7(7):e42088
pubmed: 22848713
Science. 2015 Nov 20;350(6263):981-5
pubmed: 26472762
J Cereb Blood Flow Metab. 2017 Mar;37(3):801-813
pubmed: 27006446
Nature. 2013 Mar 14;495(7440):227-30
pubmed: 23434756
Genesis. 2004 Jan;38(1):39-50
pubmed: 14755803
Cell Immunol. 2015 Oct;297(2):69-79
pubmed: 26163773
Nat Neurosci. 2020 Mar;23(3):351-362
pubmed: 32042176
Nature. 2010 May 27;465(7297):483-6
pubmed: 20445537
Am J Pathol. 1994 Jan;144(1):188-99
pubmed: 8291608
Adv Immunol. 2020;145:37-53
pubmed: 32081199
Stroke. 2009 May;40(5):1849-57
pubmed: 19265055
Blood. 2001 Jan 15;97(2):367-75
pubmed: 11154210
Immunity. 2017 Mar 21;46(3):474-487
pubmed: 28314594
Blood. 2010 May 6;115(18):3835-42
pubmed: 20215643
J Exp Med. 2004 Nov 1;200(9):1145-56
pubmed: 15520246
Nat Rev Immunol. 2020 Sep;20(9):552-565
pubmed: 32107466
Brain. 2008 Jul;131(Pt 7):1681-3
pubmed: 18586760
Nat Immunol. 2017 Feb;18(2):132-141
pubmed: 28092376
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18324-9
pubmed: 22021440
Nat Neurosci. 2010 Jan;13(1):133-40
pubmed: 20023653
Nat Immunol. 2017 Oct;18(10):1117-1127
pubmed: 28805812
J Neurosci. 2002 Jul 15;22(14):5865-78
pubmed: 12122049
Sci Immunol. 2019 May 31;4(35):
pubmed: 31152090
Nature. 2021 Feb;590(7846):473-479
pubmed: 33408417
Pharmacol Res. 2019 Sep;147:104349
pubmed: 31315064
Front Cell Neurosci. 2014 May 28;8:154
pubmed: 24920943
Exp Transl Stroke Med. 2010 Jul 19;2(1):13
pubmed: 20642841
Sci Rep. 2018 Apr 12;8(1):5913
pubmed: 29651133
Nature. 2015 Jul 16;523(7560):337-41
pubmed: 26030524
Annu Rev Immunol. 2020 Apr 26;38:597-620
pubmed: 32340575
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2704-9
pubmed: 24550298
Nat Commun. 2017 Nov 10;8(1):1434
pubmed: 29127332
Trends Immunol. 2004 Jun;25(6):306-14
pubmed: 15145320
Nature. 2019 Jan;565(7738):246-250
pubmed: 30602786
Nature. 2020 Jan;577(7790):399-404
pubmed: 31915375
Neuron. 2018 Oct 24;100(2):375-388
pubmed: 30359603
Front Immunol. 2019 Oct 10;10:2337
pubmed: 31649664
J Exp Med. 2015 Jun 29;212(7):991-9
pubmed: 26077718
Nat Commun. 2020 Apr 14;11(1):1773
pubmed: 32286313
J Neuroimmunol. 2015 May 15;282:39-44
pubmed: 25903727
Cell. 2006 Sep 22;126(6):1121-33
pubmed: 16990136